The beneficial effect of SGLT2 inhibitors in HF hassubsequently been corroborated in patients with HF and reduced or preserved LVEF,irrespective of the presence of diabetes [28, 29, 30, 31] (Table 2). The gene discussed is SLC5A2; the disease is diabetes mellitus.